Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Britain's new bonkers EV: Callum Skye is an £80k electric buggy built in Warwickshire
A ride on a fast catamaran led Lindsey Vonn to join U.S. SailGP Team's board of directors
Siblings trying to make US water polo teams for Paris Olympics
Mets ace Kodai Senga faces hitters for the first time since his shoulder injury
Severino finds his old form and takes a no
De La Cruz homers and Lodolo strikes out 11 in a combined 4
Grant Shapps vows he WILL find more planes for mass parachute drop to mark 80th anniversary of D
ICJ will rule on Nicaragua's ask for halt on German weapons sales to Israel